Supplementary Table 1. Baseline characteristics of the EsDEPACS participants

	Followed-up after baseline evaluation			Exited after baseline evaluation (N=49)
	Escitalopram (N=104)	Placebo (N=102)	Total (N=206)	
Socio-demographic characteristics				
Age, mean (SD) year	59.9 (10.9)	58.6 (10.6)	59.2 (10.7)	62.1 (10.0)
Gender, N (%) men	67 (64.4)	58 (56.9)	125 (60.7)	29 (59.2)
Education, mean (SD) year	9.4 (4.2)	9.4 (4.1)	9.5 (4.1)	8.8 (4.3)
Living alone, N (%)	8 (7.7)	12 (11.8)	20 (9.7)	6 (12.2)
Housing, N (%) rented	15 (14.4)	22 (21.6)	37 (18.0)	6 (12.2)
Currently unemployed, N (%)	45 (43.3)	51 (50.0)	96 (46.6)	26 (53.1)
Depression characteristics				
Previous depression, N (%)	6 (5.8)	5 (4.9)	11 (5.3)	1 (2.0)
Family history of depression, N (%)	3 (2.9)	5 (4.9)	8 (3.9)	1 (2.0)
HAMD, mean (SD) score	15.8 (5.0)	15.1 (4.4)	15.5 (4.7)	16.2 (5.5)
Cardiac risk factors, N (%)				
Previous ACS	6 (5.8)	6 (5.9)	12 (5.8)	2 (4.1)
Family history of ACS	4 (3.8)	3 (2.9)	7 (3.4)	5 (10.2)
Hypertension	60 (57.7)	60 (58.8)	120 (58.3)	29 (59.2)
Diabetes mellitus	34 (32.7)	30 (29.4)	64 (31.1)	10 (20.4)
Hypercholesterolemia	50 (48.1)	47 (46.1)	97 (47.1)	29 (59.2)
Obesity	40 (38.5)	48 (47.1)	88 (42.7)	17 (34.7)
Current smoker	36 (34.6)	28 (27.5)	64 (31.1)	13 (26.5)
Current cardiac status				
Killip class >1, N (%)	14 (13.5)	19 (18.6)	33 (16.0)	15 (30.6)*
LVEF, mean (SD) %	59.9 (11.0)	62.7 (9.9)	61.3 (10.5)	59.8 (11.3)
Troponin I, mean (SD) mg/dL	9.6 (8.6)	9.6 (7.8)	9.6 (8.2)	11.3 (9.8)
CK-MB, mean (SD) mg/dL	14.8 (14.5)	14.2 (19.8)	14.5 (17.3)	26.6 (35.2)*

No significant differences were found between the escitalopram and placebo groups; and no significant differences were found between those followed-up and exited after baseline evaluation except for the Killip class (p=0.019) and serum CK-MB level (p=0.022)* using t-tests, χ^2 tests, or Fisher's exact tests, as appropriate. EsDEPACS: Escitalopram for DEPression in Acute Coronary Syndrome study, HAMD: Hamilton Depression Rating Scale, ACS: acute coronary syndrome, LVEF: left ventricular ejection fraction, CK-MB: creatine kinase-MB